Assessing Trifecta Achievement after Percutaneous Cryoablation of Small Renal Masses: Results from a Multi-Institutional Collaboration.


Journal

Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208

Informations de publication

Date de publication:
03 Aug 2022
Historique:
received: 30 06 2022
revised: 28 07 2022
accepted: 01 08 2022
entrez: 26 8 2022
pubmed: 27 8 2022
medline: 30 8 2022
Statut: epublish

Résumé

Background and Objectives: To assess efficacy and safety of Percutaneous Cryoablation (PCA) of small renal masses (SRMs) using Trifecta outcomes in a large cohort of patients who were not eligible for surgery. Materials and methods: All PCAs performed in four different centers between September 2009 and September 2019 were retrospectively evaluated. Patients were divided in two different groups depending on masses dimensional criteria: Group-A: diameter ≤ 25 mm and Group-B: diameter > 25 mm. Complications rates were reported and classified according to the Clavien−Dindo system. The estimate glomerular filtration rate (eGFR) was calculated before PCA and during follow-up schedule. Every patient received a Contrast Enhanced Ultrasound (CEUS) evaluation on the first postoperative day. Radiological follow-up was taken at 3, 6, and 12 months for the first year, then yearly. Radiological recurrence was defined as a contrast enhancement persistence and was reported in the study. Finally, Trifecta outcome, which included complications, RFS, and preservation of eGFR class, was calculated for every procedure at a median follow-up of 32 months. Results: The median age of the patients was 74 years. Group-A included 200 procedures while Group-B included 140. Seventy-eight patients were eligible for Trifecta evaluation. Trifecta was achieved in 69.6% of procedures in Group-A, 40.6% in Group-B (p = 0.02). We observed an increased rate of complication in Group-B (13.0% vs. 28.6; p < 0.001). However, 97.5% were <II Clavien−Dindo grade. No differences were found between the two groups regarding eGFR before and after treatment. Further, 24-months RFS rates were respectively 98.0% for Group-A and 92.1% in Group-B, while at 36 months were respectively 94.5% and 87.5% (p = 0.08). Conclusions: PCA seems to be a safe and effective treatment for SRM but in the need of more strict dimensional criteria to achieve a higher possible success rate.

Identifiants

pubmed: 36013508
pii: medicina58081041
doi: 10.3390/medicina58081041
pmc: PMC9412454
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Références

Eur Urol. 2009 Nov;56(5):786-93
pubmed: 19665284
J Urol. 2013 Jan;189(1):36-42
pubmed: 23164381
Clin Genitourin Cancer. 2022 Jul 16;:
pubmed: 35965197
Eur Urol Oncol. 2021 Apr;4(2):256-263
pubmed: 33384274
Minerva Urol Nefrol. 2020 Dec;72(6):647-649
pubmed: 32432437
Int J Urol. 2015 Nov;22(11):1000-5
pubmed: 26251228
BJU Int. 2021 Oct;128(4):440-450
pubmed: 33991045
Minerva Urol Nephrol. 2021 Aug;73(4):518-524
pubmed: 33769011
J Endourol. 2013 Dec;27(12):1468-70
pubmed: 24074156
Eur Urol Focus. 2021 Nov;7(6):1254-1259
pubmed: 32912840
J Urol. 2017 Sep;198(3):520-529
pubmed: 28479239
Eur Urol. 2015 May;67(5):913-24
pubmed: 25616710
Oncotarget. 2017 Apr 18;8(16):27635-27644
pubmed: 28199973
Minerva Urol Nephrol. 2022 Apr;74(2):194-202
pubmed: 34308610
Eur Urol. 2016 Jan;69(1):116-28
pubmed: 25819723
AJR Am J Roentgenol. 2020 Jul;215(1):242-247
pubmed: 32286877
J Endourol. 2020 Feb;34(2):233-239
pubmed: 31724433
J Endourol. 2012 Nov;26(11):1413-9
pubmed: 22642574
Eur Urol Oncol. 2019 Mar;2(2):207-213
pubmed: 31017098
Curr Urol Rep. 2014 Apr;15(4):396
pubmed: 24623576
J Vasc Interv Radiol. 2012 Jan;23(1):48-54
pubmed: 22037491
Cardiovasc Intervent Radiol. 2021 Jun;44(6):892-900
pubmed: 33388867
World J Urol. 2018 Sep;36(9):1341-1353
pubmed: 29610964
J Ultrasound Med. 2017 Feb;36(2):301-310
pubmed: 27914172
Minerva Urol Nephrol. 2022 Jun;74(3):321-328
pubmed: 33781019
World J Urol. 2014 Feb;32(1):257-63
pubmed: 24013181
Scand J Urol. 2020 Apr;54(2):122-127
pubmed: 32153242
J Med Imaging Radiat Oncol. 2021 Jun;65(3):272-278
pubmed: 33547767
Eur Urol. 2020 Jan;77(1):95-100
pubmed: 30898407
Minerva Urol Nefrol. 2020 Feb;72(1):109-113
pubmed: 31833726
BJU Int. 2012 Aug;110(4):510-6
pubmed: 22304329
Eur Urol Focus. 2018 Mar;4(2):280-287
pubmed: 28753765
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Radiographics. 2010 Jul-Aug;30(4):887-900
pubmed: 20631358
J Natl Cancer Inst. 2006 Sep 20;98(18):1331-4
pubmed: 16985252
Urology. 2014 May;83(5):1081-7
pubmed: 24560975
Urology. 2015 Apr;85(4):850-5
pubmed: 25704992
J Endourol. 2008 May;22(5):963-7
pubmed: 18643721
J Cancer. 2019 Jan 29;10(5):1226-1236
pubmed: 30854132
BJU Int. 2015 Sep;116(3):407-14
pubmed: 25220543
Urol Oncol. 2020 Dec;38(12):938.e1-938.e7
pubmed: 33036899

Auteurs

Andrea Piasentin (A)

Urology Clinic, Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Strada di Fiume 447, 34149 Trieste, Italy.

Francesco Claps (F)

Urology Clinic, Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Strada di Fiume 447, 34149 Trieste, Italy.

Tommaso Silvestri (T)

Department of Urology, San Bassiano Hospital, 36061 Bassano del Grappa, Italy.

Giacomo Rebez (G)

Urology Clinic, Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Strada di Fiume 447, 34149 Trieste, Italy.

Fabio Traunero (F)

Urology Clinic, Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Strada di Fiume 447, 34149 Trieste, Italy.

Maria Carmen Mir (MC)

Department of Urology, Fundacion Instituto Valenciano Oncologia, FIVO, 46009 Valencia, Spain.

Michele Rizzo (M)

Urology Clinic, Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Strada di Fiume 447, 34149 Trieste, Italy.

Antonio Celia (A)

Department of Urology, San Bassiano Hospital, 36061 Bassano del Grappa, Italy.

Calogero Cicero (C)

Radiology Department, San Bassiano Hospital, ULSS 7 Pedemontana, 36061 Bassano del Grappa, Italy.

Martina Urbani (M)

Radiology Department, Centro di Riferimento Oncologico (CRO), 33081 Aviano, Italy.

Luca Balestreri (L)

Radiology Department, Centro di Riferimento Oncologico (CRO), 33081 Aviano, Italy.

Lisa Pola (L)

Department of Urology, ULSS 3 Serenissima, 30031 Dolo, Italy.

Fulvio Laganà (F)

Department of Urology, ULSS 3 Serenissima, 30031 Dolo, Italy.

Stefano Cernic (S)

Radiology Department, Azienda Universitaria Giuliano Isontina (ASUGI), Università degli Studi di Trieste, 34127 Trieste, Italy.

Maria Assunta Cova (MA)

Radiology Department, Azienda Universitaria Giuliano Isontina (ASUGI), Università degli Studi di Trieste, 34127 Trieste, Italy.

Michele Bertolotto (M)

Radiology Department, Azienda Universitaria Giuliano Isontina (ASUGI), Università degli Studi di Trieste, 34127 Trieste, Italy.

Carlo Trombetta (C)

Urology Clinic, Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Strada di Fiume 447, 34149 Trieste, Italy.

Giovanni Liguori (G)

Urology Clinic, Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Strada di Fiume 447, 34149 Trieste, Italy.

Nicola Pavan (N)

Urology Clinic, Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Strada di Fiume 447, 34149 Trieste, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH